Novo Nordisk

News

Hims & Hers launches weight-loss business in UK

Hims & Hers has launched its direct-to-consumer weight-loss therapy channel in the UK, offering Wegovy, Mounjaro, and OTC option Orlos.

News

Novo Nordisk files Wegovy product that claimed rapid voucher

Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.

News

Data sets up phase 3 trials for Novo's amycretin in diabetes

Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.

News

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

GLP-1 agonists have been shown to be beneficial in a lengthening list of diseases, but it seems Alzheimer's disease may not be among them.

News

Overweight man leans on office desk with female co-worker

Waltz dances into direct-to-employer sales of obesity drugs

Waltz Health is planning to disrupt the weight-loss therapy market in the US with a new direct-to-employer sales channel.

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

Hims & Hers launches weight-loss business in UK

Novo Nordisk files Wegovy product that claimed rapid voucher

Data sets up phase 3 trials for Novo's amycretin in diabetes

Disappointment as Novo's oral GLP-1 fails in Alzheimer's

Waltz dances into direct-to-employer sales of obesity drugs

Agios shares slump on sickle cell disease data

Datroway filed for TNBC in EU after data delay

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks